Ann: Race investor briefing invitation, page-22

Checked the presso was very informative and thumbs up to answering questions that ppl have raised including myself.

Like the staircase analogue and building on this:

1. We have purchased an old drug that was lost.
2. The drug is a great treatment for AML/cancer.
3. Dr T has a hunch of cardio protection.
3. A search shows it is no. 1 FTO inhibitor.
4. We think it works as an FTO inhibitor in humans.
5. Preclinical work correlates to FTO and cardio protection.

<<We are about here>>

6. Finalise preclinical work in the lab to check results.
7. Design trials and focus of therapeutic targets.
8. Obtain relevant approvals for trials.
9. Commence and run trials. EMD / AML in progress only
10. Obtain readouts and results.

<<Market wants us to be here>>

11. FTO is an effective target in humans.
12. Zantrene does inhibit FTO, killing cancer, synergising with other drugs and filling unmet clinical needs.
13. We know Zantrene is both anti cancer / cardio protective in humans and has greater efficacy than Doxo.
14. Zantrene targets and kills EMD AML and supported by P2 data for which there is currently no SoC.
15. IND applications submitted for Trials in US

<<On the radar with Pharma>>

16. Published high quality data on each trial indication.
17. Plans for approval and commercialisation in progress.
18. x3 World first Pathways that Zantrene kills cancer.
19. 29+ other cancer indication targets.
20. Synergise with Pharma pipeline therapies.

Then ready for transaction, As easy as pulling an Elephant out of a hat!

<<Shareholders want to be here>>

~ R E T I R E M E N T ~